The core information from DataM Intelligence indicates that the market was valued at USD 13.22 billion in 2024 and is projected to double to USD 28.10 billion by 2033 due to advancements in precision medicine, hormonal therapies, and targeted radioligands. Segmentation analysis breaks down the market by therapy type, dominated by hormonal therapy (57% share), as well as by administration route (mostly oral) and distribution channel (led by hospital pharmacies). Furthermore, the report highlights key growth drivers like rising global incidence and provides competitive analysis, naming major players such as Novartis AG and Johnson & Johnson, and discusses regional revenue leadership by the United States. Continue reading →